GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology. Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders: In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and

Most platform biotechs don’t fail on science—they fail because investors don’t believe the team can turn that science into a real, defensible engine. This post breaks down what VCs are actually trying to de‑risk in a platform biotech, how your first five hires map to those concerns, and the concrete artifacts (org map, hiring plan, scorecards, RA/QA and BD thinking) you can bring to a pitch to show you’re building a fundable team, not just a cool idea.

Rare Disease as a Strategic Growth Engine Rare disease is no longer just a scientific or regulatory story — it is a commercial one. But in rare disease, “the market” is not an abstract concept. It is a small, tightly connected ecosystem of patients, caregivers, advocates, clinicians, and payers who all know each other — and who expect to be true partners. Speaking to many global commercial leader over the last few weeks Patient advocacy has been a re-occurring theme. For glob

For decades, families affected by rare diseases have heard the same heartbreaking message: ‘There is no approved treatment yet.’ In 2026, that story is finally changing. From the first-ever approval for Menkes disease to a landmark FDA policy shift for gene therapies, the rare disease landscape is transforming at a pace never seen before. Here’s what you need to know.